MX2024004647A - Celulas eucariotas que comprenden polinucleotidos de virus asociados a adenovirus. - Google Patents
Celulas eucariotas que comprenden polinucleotidos de virus asociados a adenovirus.Info
- Publication number
- MX2024004647A MX2024004647A MX2024004647A MX2024004647A MX2024004647A MX 2024004647 A MX2024004647 A MX 2024004647A MX 2024004647 A MX2024004647 A MX 2024004647A MX 2024004647 A MX2024004647 A MX 2024004647A MX 2024004647 A MX2024004647 A MX 2024004647A
- Authority
- MX
- Mexico
- Prior art keywords
- polynucleotides
- aav
- eukaryotic cells
- cells
- adenovirus
- Prior art date
Links
- 102000040430 polynucleotide Human genes 0.000 title abstract 6
- 108091033319 polynucleotide Proteins 0.000 title abstract 6
- 239000002157 polynucleotide Substances 0.000 title abstract 6
- 210000003527 eukaryotic cell Anatomy 0.000 title abstract 4
- 241000701161 unidentified adenovirus Species 0.000 title abstract 2
- 241000700605 Viruses Species 0.000 title 1
- 108090000565 Capsid Proteins Proteins 0.000 abstract 1
- 102100023321 Ceruloplasmin Human genes 0.000 abstract 1
- 241000702421 Dependoparvovirus Species 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 abstract 1
- 210000004962 mammalian cell Anatomy 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14151—Methods of production or purification of viral material
- C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163256730P | 2021-10-18 | 2021-10-18 | |
| PCT/US2022/078266 WO2023069926A1 (en) | 2021-10-18 | 2022-10-18 | Eukaryotic cells comprising adenovirus-associated virus polynucleotides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024004647A true MX2024004647A (es) | 2024-05-02 |
Family
ID=84389146
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024004647A MX2024004647A (es) | 2021-10-18 | 2022-10-18 | Celulas eucariotas que comprenden polinucleotidos de virus asociados a adenovirus. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12234472B2 (enExample) |
| EP (1) | EP4419696A1 (enExample) |
| JP (1) | JP2024537896A (enExample) |
| KR (1) | KR20240099288A (enExample) |
| CN (1) | CN118103517A (enExample) |
| AU (1) | AU2022373653A1 (enExample) |
| CA (1) | CA3234939A1 (enExample) |
| IL (1) | IL312124A (enExample) |
| MX (1) | MX2024004647A (enExample) |
| TW (1) | TW202323529A (enExample) |
| WO (1) | WO2023069926A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024263705A2 (en) | 2023-06-20 | 2024-12-26 | Regeneron Pharmaceuticals, Inc. | Methods for purifying filled adeno-associated virus capsids |
Family Cites Families (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5464758A (en) | 1993-06-14 | 1995-11-07 | Gossen; Manfred | Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters |
| US5658785A (en) | 1994-06-06 | 1997-08-19 | Children's Hospital, Inc. | Adeno-associated virus materials and methods |
| US5985846A (en) | 1995-06-07 | 1999-11-16 | Baylor College Of Medicine | Gene therapy for muscular dystrophy |
| US7232899B2 (en) | 1996-09-25 | 2007-06-19 | The Scripps Research Institute | Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use |
| WO1998054345A1 (en) | 1997-05-30 | 1998-12-03 | Baxter International Inc. | Mini-adenoviral vector |
| WO1999053085A2 (en) | 1998-04-15 | 1999-10-21 | The Research Foundation Of State University Of New York | Selective regulation of adenovirus production |
| US5981225A (en) | 1998-04-16 | 1999-11-09 | Baylor College Of Medicine | Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same |
| US5989910A (en) | 1998-08-03 | 1999-11-23 | University Of Lausanne | Potent genetic switch allowing regulated gene expression in eukaryotic cells |
| US6423544B1 (en) | 1998-12-31 | 2002-07-23 | Chiron Corporation | Compositions and methods for producing recombinant virions |
| MY123548A (en) | 1999-11-08 | 2006-05-31 | Shell Int Research | Method and system for suppressing and controlling slug flow in a multi-phase fluid stream |
| DE19955558C2 (de) | 1999-11-18 | 2003-03-20 | Stefan Kochanek | Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren |
| US6558948B1 (en) | 1999-11-23 | 2003-05-06 | Stefan Kochanek | Permanent amniocytic cell line, its production and use for the production of gene transfer vectors |
| ATE440133T1 (de) | 2001-02-21 | 2009-09-15 | Cevec Pharmaceuticals Gmbh | Pigmentepithelzelle des auges, ihre herstellung und verwendung in der therapie einer augen- oder zns-erkrankung |
| ES2439874T3 (es) | 2002-05-29 | 2014-01-27 | Regeneron Pharmaceuticals, Inc. | Sistema de expresión en eucariotas inducible |
| US8673589B2 (en) | 2002-05-29 | 2014-03-18 | Regeneron Pharmaceuticals, Inc. | Inducible eukaryotic expression system |
| WO2005106046A1 (en) | 2004-05-03 | 2005-11-10 | Stefan Kochanek | Modified viral vector particles |
| DE102005054628A1 (de) | 2005-11-16 | 2007-05-24 | Cevec Pharmaceuticals Gmbh | Verfahren zur Herstellung von permanenten humanen Zelllinien |
| WO2007084773A2 (en) * | 2006-01-20 | 2007-07-26 | University Of North Carolina At Chapel Hill | Enhanced production of infectious parvovirus vectors in insect cells |
| AU2007249695A1 (en) | 2006-05-15 | 2007-11-22 | Paratek Pharmaceuticals, Inc. | Methods of regulating expression of genes or of gene products using substituted tetracycline compounds |
| EP2150617B1 (en) | 2007-06-04 | 2014-10-22 | Regeneron Pharmaceuticals, Inc. | Enhanced expression and stability regions |
| US8852926B2 (en) | 2007-10-25 | 2014-10-07 | Board Of Trustees Of Southern Illinois University | Genetic selection system for identification of MicroRNA target genes |
| DE102009003439A1 (de) | 2009-02-05 | 2010-08-26 | Cevec Pharmaceuticals Gmbh | Neue permanente humane Zelllinie |
| US8734809B2 (en) * | 2009-05-28 | 2014-05-27 | University Of Massachusetts | AAV's and uses thereof |
| WO2011126808A2 (en) * | 2010-03-29 | 2011-10-13 | The Trustees Of The University Of Pennsylvania | Pharmacologically induced transgene ablation system |
| US8927514B2 (en) | 2010-04-30 | 2015-01-06 | City Of Hope | Recombinant adeno-associated vectors for targeted treatment |
| US9839696B2 (en) | 2010-04-30 | 2017-12-12 | City Of Hope | Recombinant adeno-associated vectors for targeted treatment |
| EP2606128B1 (de) | 2010-08-16 | 2014-09-10 | CEVEC Pharmaceuticals GmbH | Permanente humane amniozyten zellinie zur herstellung von influenzaviren |
| EP2662451A1 (en) | 2012-05-07 | 2013-11-13 | Stefan Kochanek | Nucleic acid construct and use of the same |
| EP2711428A1 (en) | 2012-09-21 | 2014-03-26 | Lonza Biologics plc. | Site-specific integration |
| JP6676526B2 (ja) | 2013-08-06 | 2020-04-08 | ロンザ バイオロジクス ピーエルシー | 組換えタンパク質の生産のための哺乳動物生産細胞の生成のための手段及び方法 |
| GB201322798D0 (en) | 2013-12-20 | 2014-02-05 | Oxford Biomedica Ltd | Production system |
| CA2942515C (en) | 2014-03-18 | 2025-12-09 | University Of Massachusetts | Raav-based compositions and methods for treating amyotrophic lateral sclerosis |
| BR112017008022A2 (pt) | 2014-10-23 | 2018-02-20 | Regeneron Pharmaceuticals, Inc. | célula, polinucleotídeo, veículo, e, métodos para modificação de um genoma de células cho e para preparação de uma proteína de interesse. |
| EP3042952A1 (en) | 2015-01-07 | 2016-07-13 | CEVEC Pharmaceuticals GmbH | O-glycan sialylated recombinant glycoproteins and cell lines for producing the same |
| TWI707951B (zh) | 2015-04-08 | 2020-10-21 | 美商健臻公司 | 過大腺相關載體之製造 |
| EP3205719A1 (en) | 2016-02-15 | 2017-08-16 | CEVEC Pharmaceuticals GmbH | Cell lines for producing recombinant glycoproteins with di-antennary n-glycans, methods using the same, and recombinant glycoproteins |
| GB201603577D0 (en) | 2016-03-01 | 2016-04-13 | Oxford Genetics Ltd | Promoter |
| WO2017173043A1 (en) | 2016-03-30 | 2017-10-05 | Spark Therapeutics, Inc. | Cell line for recombinant protein and/or viral vector production |
| SG11201807885PA (en) | 2016-04-20 | 2018-10-30 | Regeneron Pharma | Compositions and methods for making antibodies based on use of expression-enhancing loci |
| GB2549809C (en) | 2016-06-23 | 2022-11-30 | Univ Oxford Innovation Ltd | Vector |
| WO2018031769A1 (en) | 2016-08-10 | 2018-02-15 | Lonza Inc. | Biopharmaceutical batch recipe review by exception |
| WO2018146588A1 (en) | 2017-02-08 | 2018-08-16 | Friedrich Miescher Institute For Biomedical Research | Synp88, a promoter for the specific expression of genes in retinal ganglion cells |
| JP7467119B2 (ja) | 2017-02-17 | 2024-04-15 | ロンザ リミテッド | 発現困難タンパク質のための多部位ｓｓｉ細胞 |
| KR102719587B1 (ko) | 2017-02-17 | 2024-10-17 | 론자 리미티드 | 아데노-관련 바이러스 생산을 위한 포유동물 세포 |
| CN110419011A (zh) | 2017-03-17 | 2019-11-05 | 龙沙有限公司 | 自动化批量数据分析 |
| WO2018175775A1 (en) | 2017-03-22 | 2018-09-27 | Dimension Therapeutics | Cell culture methods involving hdac inhibitors or rep proteins |
| EP3382014A1 (en) | 2017-03-29 | 2018-10-03 | CEVEC Pharmaceuticals GmbH | Recombinant glycoproteins with reduced antennary fucosylation |
| GB201705927D0 (en) | 2017-04-12 | 2017-05-24 | Oxford Genetics Ltd | Vector |
| EP3612635A2 (en) | 2017-04-18 | 2020-02-26 | GlaxoSmithKline Intellectual Property Development Limited | Methods for adeno-associated viral vector production |
| CN110892064A (zh) | 2017-07-25 | 2020-03-17 | 牛津遗传学有限公司 | 腺病毒载体 |
| EP3441471A1 (en) | 2017-08-08 | 2019-02-13 | CEVEC Pharmaceuticals GmbH | Use of constitutively active variants of growth factor receptors as selection makers for the generation of stable producer cell lines |
| EP3456822A1 (en) | 2017-09-19 | 2019-03-20 | CEVEC Pharmaceuticals GmbH | Inducible aav rep genes |
| US12123027B2 (en) | 2017-10-12 | 2024-10-22 | Ascend Advanced Therapies Limited | Life-cycle-defective adenovirus helper viruses, their production and use for producing rAAV |
| AU2018356538B2 (en) | 2017-10-25 | 2023-09-28 | Nouscom Ag | Eukaryotic cell line |
| IL275462B2 (en) | 2017-12-22 | 2026-01-01 | Genentech Inc | Targeted integration of nucleic acids |
| GB201800903D0 (en) | 2018-01-19 | 2018-03-07 | Oxford Genetics Ltd | Vectors |
| WO2019157239A1 (en) | 2018-02-08 | 2019-08-15 | David Kiewlich | Plasmid vectors for expression of large nucleic acid transgenes |
| GB201802122D0 (en) | 2018-02-09 | 2018-03-28 | Univ Oxford Innovation Ltd | Product and use |
| GB201814590D0 (en) | 2018-09-07 | 2018-10-24 | Oxford Biomedica Ltd | Viral vector production system |
| EP3597172A1 (en) | 2018-07-16 | 2020-01-22 | Kao Germany GmbH | Hair treatment composition |
| EP3833745A1 (en) * | 2018-08-10 | 2021-06-16 | REGENXBIO Inc. | Scalable method for recombinant aav production |
| EP3841193A1 (en) | 2018-08-21 | 2021-06-30 | Lonza Ltd. | A process for creating reference data for predicting concentrations of quality attributes |
| GB201814141D0 (en) | 2018-08-30 | 2018-10-17 | Univ Oxford Innovation Ltd | Method and compositions for producing a virus |
| JP7549582B2 (ja) | 2018-10-01 | 2024-09-11 | ロンザ リミテッド | 予測可能かつ安定な導入遺伝子発現を有するｓｓｉ細胞および形成の方法 |
| AU2019362280B2 (en) | 2018-10-17 | 2026-03-19 | Children's Medical Research Institute | Nucleic acid molecules and methods for AAV vector selection |
| GB201816919D0 (en) | 2018-10-17 | 2018-11-28 | Glaxosmithkline Ip Dev Ltd | Adeno-associated viral vector producer cell lines |
| WO2020084034A1 (en) | 2018-10-26 | 2020-04-30 | F. Hoffmann-La Roche Ag | Multispecific antibody screening method using recombinase mediated cassette exchange |
| CN113396222A (zh) * | 2018-12-21 | 2021-09-14 | 隆萨沃克斯维尔股份有限公司 | 腺相关病毒(aav)生产细胞系和相关方法 |
| KR20210108406A (ko) | 2018-12-21 | 2021-09-02 | 론자 워커스빌 아이엔씨. | 바이러스 벡터의 자동화된 생산 |
| AU2019403279A1 (en) | 2018-12-21 | 2021-07-01 | Genentech, Inc. | Targeted integration of nucleic acids |
| GB201901571D0 (en) | 2019-02-05 | 2019-03-27 | Oxford Genetics Ltd | Inducible AAV sysyem |
| GB201902068D0 (en) | 2019-02-14 | 2019-04-03 | Cambridge Entpr Ltd | Methods of reactivating proliferative capacity non-proliferative tissues |
| CN113544509A (zh) | 2019-03-08 | 2021-10-22 | 牛津遗传学有限公司 | 选择抗体的方法 |
| SG11202110904PA (en) | 2019-04-12 | 2021-10-28 | Ultragenyx Pharmaceutical Inc | Engineered producer cell lines and methods of making and using the same |
| JP7663513B2 (ja) | 2019-05-16 | 2025-04-16 | トラスティーズ オブ ボストン ユニバーシティ | 調節された合成遺伝子発現システム |
| AU2020284255A1 (en) | 2019-05-30 | 2022-01-06 | Solid Biosciences Inc. | Recombinant herpesvirales vector |
| WO2021127432A1 (en) | 2019-12-19 | 2021-06-24 | Lonza Walkersville, Inc. | Automated production of viral vectors |
| CN115315518A (zh) | 2020-01-17 | 2022-11-08 | 阿斯克肋匹奥生物制药公司 | 重组aav的生产 |
| GB202001484D0 (en) | 2020-02-04 | 2020-03-18 | Oxford Genetics Ltd | DNA amplification method |
| CN115298316B (zh) | 2020-02-04 | 2025-02-14 | 牛津遗传学有限公司 | 用于制备腺相关病毒载体的方法 |
| US20230235353A1 (en) | 2020-03-19 | 2023-07-27 | Ultragenyx Pharmaceutical Inc. | Compositions and methods for reducing reverse packaging of cap and rep sequences in recombinant aav |
| EP4150097A1 (en) | 2020-05-15 | 2023-03-22 | Ivexsol, Inc. | Compositions and methods for producing stable viral vector producer cells for cell and gene therapy |
| CN113699147B (zh) | 2020-05-22 | 2023-06-09 | 深圳市深研生物科技有限公司 | 基于四环素和Cumate的共调控序列 |
| US20230279427A1 (en) | 2020-07-24 | 2023-09-07 | Regents Of The University Of Minnesota | Cell lines for recombinant aav production and aav-implemented protein production |
| GB202013060D0 (en) | 2020-08-21 | 2020-10-07 | Oxford Genetics Ltd | Cell line |
| GB202013057D0 (en) | 2020-08-21 | 2020-10-07 | Oxford Genetics Ltd | Method of making recombinant aavs |
| WO2022038367A1 (en) | 2020-08-21 | 2022-02-24 | Oxford Genetics Limited | Process for making a recombinant aav library |
| EP4006141A1 (en) | 2020-11-25 | 2022-06-01 | CEVEC Pharmaceuticals GmbH | Method for the production of aav |
| KR20230142712A (ko) | 2021-02-11 | 2023-10-11 | 론자 휴스턴, 아이엔씨. | 아데노-연관된 바이러스(aav) 생산 |
| JP2024517104A (ja) | 2021-04-19 | 2024-04-19 | オックスフォード ジェネティクス リミテッド | Ｃａｒｅエレメントを用いたｄｎａ増幅方法 |
| US20230257831A1 (en) | 2021-09-01 | 2023-08-17 | Oxford Genetics Limited | Method for determining aav titre |
| CA3235566A1 (en) | 2021-10-18 | 2023-04-27 | Michael Goren | Mammalian cells comprising integrated cas9 genes to produce stable integration sites, and mammalian cells comprising stable integration sites and other sites |
| CN118159660A (zh) | 2021-10-18 | 2024-06-07 | 瑞泽恩制药公司 | 多核苷酸的受控转录 |
| WO2023173105A2 (en) | 2022-03-10 | 2023-09-14 | Saliogen Therapeutics, Inc. | Tetracycline inducer/repressor system and simplified viral particle production |
-
2022
- 2022-10-18 TW TW111139399A patent/TW202323529A/zh unknown
- 2022-10-18 US US18/047,341 patent/US12234472B2/en active Active
- 2022-10-18 MX MX2024004647A patent/MX2024004647A/es unknown
- 2022-10-18 CN CN202280069671.6A patent/CN118103517A/zh active Pending
- 2022-10-18 AU AU2022373653A patent/AU2022373653A1/en active Pending
- 2022-10-18 CA CA3234939A patent/CA3234939A1/en active Pending
- 2022-10-18 IL IL312124A patent/IL312124A/en unknown
- 2022-10-18 EP EP22818152.5A patent/EP4419696A1/en active Pending
- 2022-10-18 JP JP2024522668A patent/JP2024537896A/ja active Pending
- 2022-10-18 WO PCT/US2022/078266 patent/WO2023069926A1/en not_active Ceased
- 2022-10-18 KR KR1020247016164A patent/KR20240099288A/ko active Pending
-
2025
- 2025-01-15 US US19/022,099 patent/US20250154524A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022373653A1 (en) | 2024-05-02 |
| JP2024537896A (ja) | 2024-10-16 |
| CN118103517A (zh) | 2024-05-28 |
| US20230193312A1 (en) | 2023-06-22 |
| TW202323529A (zh) | 2023-06-16 |
| IL312124A (en) | 2024-06-01 |
| US12234472B2 (en) | 2025-02-25 |
| WO2023069926A1 (en) | 2023-04-27 |
| CA3234939A1 (en) | 2023-04-27 |
| EP4419696A1 (en) | 2024-08-28 |
| KR20240099288A (ko) | 2024-06-28 |
| US20250154524A1 (en) | 2025-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ514951A (en) | Recombinant protein production in a cultured human cell | |
| WO2004075861A3 (en) | Recombinant adeno-associated virus production | |
| WO2019191633A3 (en) | Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof | |
| WO2021198706A3 (en) | Coronavirus vaccines | |
| AR020048A1 (es) | Un polipeptido dependiente de la vitamina k, una composicion farmaceutica que lo comprende, el uso del mismo para la manufactura de un medicamento, unacido nucleico aislado que codifica a dicho polipeptido y una celula hospedante de mamifero. | |
| MX2024004647A (es) | Celulas eucariotas que comprenden polinucleotidos de virus asociados a adenovirus. | |
| EA201170993A1 (ru) | Удлиненные рекомбинантные полипептиды и содержащие их композиции | |
| FI821466A7 (fi) | Bacillus-kloonausvektorit, yhdistelmä- DNA-molekyylit, niiden transformoimat Bacillus-isännät sekä menetelmätvieraiden DNA- sekvenssien ekspressiota varten sekä näiden koodaamien polypeptidien tuottamiseksi. | |
| CO6270336A2 (es) | Composiciones pepticidas que comprenden uno o mas polipetidos | |
| DE60330923D1 (de) | Menschliche Koagulationsfaktor VII Polypeptide | |
| BR112017009177A2 (pt) | vacinas terapêuticas contra hpv16 | |
| WO2024073385A3 (en) | Synthetic polypeptides and uses thereof | |
| BR0315327A (pt) | Antagonistas de il-15 | |
| MX2022014943A (es) | Polipéptidos de coronavirus 2 causante del síndrome respiratorio agudo severo (sars-cov-2) y usos de los mismos para propositos de vacuna. | |
| ES2153358T3 (es) | Procedimientos para la seleccion de celulas huespedes recombinantes que expresan altos niveles de una proteina deseada. | |
| IL84700A (en) | Hybrid proteins,dnas coding therefor,hybrid vectors containing such dnas and hosts transformed therewith,the preparation of such hybrid proteins and pharmaceutical compositions containing them | |
| EP1702071A4 (en) | TRANSACTIVATION SYSTEM FOR MAMMALIAN CELLS | |
| HRP20020549B1 (hr) | Dna koja kodira novi rg1 polipeptid | |
| WO2005014775A3 (en) | Raav compositions and methods for delivery of human factor vii polypeptides and treatment of hemophilia a | |
| DE60235985D1 (de) | Ntb-a, ein oberflächenmolekül impliziert in der aktivität natürlicher killerzellen (nk) | |
| MX2022013737A (es) | Nueva proteina y usos terapeuticos y cosmeticos de la misma. | |
| MX2023008595A (es) | Produccion mejorada de polipeptidos y virus recombinantes. | |
| CO2021018195A2 (es) | Muestra de recortes de valor en predicción reducida de mip | |
| Wang et al. | Expression and purification of recombinant human bone morphogenetic protein-7 in Escherichia coli | |
| MY198257A (en) | Gene Therapy With Dysferlin Dual Vectors |